An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Brain Metastases|Lung Cancer|Breast Cancer|Melanoma|Malignant Glioma
Interventions: DRUG: 2B3-101|DRUG: Trastuzumab|DRUG: 2B3-101 60 mg/m2 every 4 weeks|DRUG: 2B3-101 50 mg/m2 every 3 weeks
Sponsor: BBB-Therapeutics B.V.